<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253133</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC2015/34</org_study_id>
    <nct_id>NCT03253133</nct_id>
  </id_info>
  <brief_title>Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC</brief_title>
  <acronym>NIPOX</acronym>
  <official_title>Phase I Study Assessing Safety of Intraperitoneal Chemotherapy in Neoadjuvant Treatment of Peritoneal Carcinomatosis of Colorectal Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determine the maximal tolerate dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study determine the maximal tolerate dose for the patient treated by intraperitoneal
      chemotherapy in neoadjuvant treatment of peritoneal carcinomatosis of colorectal origin
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>To determine:
- Maximum tolerated dose (MTD),</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>To evaluate Long term pharmacokinetic profile of associated targeted agents in tumoral tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP neoadjuvant chemotherapy protocol:
Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.
Intravenous chemotherapy protocol:
Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Dose levels of Oxaliplatin:
4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1
Table 1: Dose levels
Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6
* Start level</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU or Folfiri</intervention_name>
    <description>Association of chemotherapy by LV5FU or Folfiri according pratician choice</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone</description>
    <arm_group_label>Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged over 18 years old

          2. Histologically confirmed diagnosis of colorectal or appendix cancer

          3. Peritoneal carcinomatosis of colorectal origin, presumed unresecable or non-optimally
             resecable, assessed by imaging (CT scan (Computed Tomography Scanner) and MRI
             (Magnetic Resonance Imaging)) or during a previous abdominal surgery

          4. Peritoneal Carcinomatosis Index &gt; 17

          5. Previous adjuvant chemotherapy is allowed

          6. One or several lines of chemotherapy are allowed

          7. Hemoglobin ≥ 10 g/dL (red blood transfusion is allowed if needed), neutrophils

               -  1.500/mm3, platelets ≥ 100.000/mm3 and white blood cells &gt; 3000 /mm3

          8. Total bilirubin ≤ 1.5 Upper limit of normal (ULN), ALT or AST ≤ 3 ULN

          9. Serum creatinine ≤ 1.5 ULN

         10. ECOG (Eastern Cooperative Oncology group) &lt; 1

         11. Life expectancy higher than 8 weeks

         12. Negative pregnancy test in women of childbearing potential

         13. Use of an effective contraceptive method during the whole treatment and up to 6 months
             after the completion of treatment

         14. Patients affiliated to a French Social Security System

         15. Signed informed consent (IC) obtained before any study specific procedures

        Exclusion Criteria:

          1. Extra peritoneal metastatic disease (except ovarian metastases and retroperitoneal
             nodes)

          2. Patients with anesthetic or medical contraindications to surgery

          3. Peripheral sensory neuropathy ≥ grade 2 at the time of signing the ICF

          4. Patients previously treated with cytoreduction and followed by an intra-peritoneal
             chemotherapy within the past 6 months.

          5. Anticancer therapy (e.g. chemotherapy, radiotherapy, targeted therapy, concomitant
             systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion

          6. History or presence of other cancer within the past 5 years (except adequately treated
             in situ carcinoma of the cervix and non-melanoma skin cancer)

          7. Pregnant or breastfeeding women

          8. Known positive test for human immunodeficiency virus (HIV), hepatitis B or C virus or
             patients with untreated serious infections

          9. Participation in another clinical trial within 30 days prior to study entry

         10. Legal incapacity or physical, psychological or mental status interfering with the
             patient's ability to sign the informed consent or to terminate the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia Sgarbura</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du Cancer de Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut réginal du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia SGARBURA</last_name>
      <phone>0033467613102</phone>
      <email>olivia.sgarbura@icm.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

